The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly ...

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 107.4% upside in the stock. While this ...

The consensus price target hints at a 49.2% upside potential for K12 (LRN). While empirical research shows that this ...

The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this ...

JEMAA vs EEM: review returns, risk and liquidity. See why JEMAA offers little edge over top emerging market ETFs—read before ...

This Friday, as part of Matchday 18 of the 2025-2026 Ligue 1 season, Paris Saint-Germain (2nd) will face Lille (4th) at the ...

Other critics have blamed passive for the prolonged slump in value investing, increased market concentration, a breakdown of ...

Affin Bank Bhd is expected to see a shift in its growth trajectory as structural changes and execution gains begin to reshape ...

Apple is upgraded to a 'strong buy' as the recent pullback offers an attractive entry ahead of 2026. See why I rate the AAPL ...

Find out more about how loss of Y chromosome in ageing males was linked to higher heart attack risk in a large prospective ...

In a note starting coverage on USL with a 'Buy' rating & target of ₹1,650, Nomura said the sector is seeing a paradigm change ...

On an annual basis, transactions totalled 470,314 units in 2025, a decrease of 1.9% from 2024. The year was characterized by ...